Literature DB >> 7031972

Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma.

E F Juniper, P A Frith, F E Hargreave.   

Abstract

We have prospectively examined in 51 patients the relationship between the level of airway responsiveness to histamine and methacholine and the minimum medications required to control asthma. First we determined the least medication that was required to control symptoms so that they did not disturb sleep, were not present on waking, and did not require use of inhaled salbutamol (200 microgram) more than four times daily. When baseline FEV1 was greater than 70% of predicted and when there had been no respiratory infection or allergen exposure for six weeks, histamine and methacholine inhalation tests were carried out on separate days to determine the provocation concentration causing a fall in FEV1 of 20% (PC20). There was a close correlation between the PC20 to the two agents. The patients were grouped into 1, those who required no medication; 2, those who required salbutamol (200 microgram) occasionally but not daily; 3, those who required daily salbutamol; and 4, those who required additional beclomethasone dipropionate. The mean PC20 was highest in group 1 and lowest in group 4; there was a significant difference between each group. The results indicate that airway responsiveness to vasoactive amines is either an important determinant of the severity of asthma and the medication requirements or a consequence of the severity of asthma. They raise the possibility that measurement of responsiveness may be useful in some patients with established asthma to substantiate or question medication needs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031972      PMCID: PMC471630          DOI: 10.1136/thx.36.8.575

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Bronchial reactivity to inhaled histamine: a method and clinical survey.

Authors:  D W Cockcroft; D N Killian; J J Mellon; F E Hargreave
Journal:  Clin Allergy       Date:  1977-05

2.  Effect of short-term, low-level nitrogen dioxide exposure on bronchial sensitivity of asthmatic patients.

Authors:  J Orehek; J P Massari; P Gayrard; C Grimaud; J Charpin
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

3.  Allergen-induced increase in non-allergic bronchial reactivity.

Authors:  D W Cockcroft; R E Ruffin; J Dolovich; F E Hargreave
Journal:  Clin Allergy       Date:  1977-11

4.  Clinical significance of bronchial sensitivity to acetylcholine and histamine in bronchial asthma.

Authors:  S Makino
Journal:  J Allergy       Date:  1966-09

5.  Perception of asthma.

Authors:  A R Rubinfeld; M C Pain
Journal:  Lancet       Date:  1976-04-24       Impact factor: 79.321

6.  Bronchoconstrictive suggestion in asthma: a role for airways hyperreactivity and emotions.

Authors:  D J Horton; W L Suda; R A Kinsman; J Souhrada; S L Spector
Journal:  Am Rev Respir Dis       Date:  1978-06

7.  Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects.

Authors:  R G Townley; U Y Ryo; B M Kolotkin; B Kang
Journal:  J Allergy Clin Immunol       Date:  1975-12       Impact factor: 10.793

8.  Airway hyperreactivity and peripheral airway dysfunction in influenza A infection.

Authors:  J W Little; W J Hall; R G Douglas; G S Mudholkar; D M Speers; K Patel
Journal:  Am Rev Respir Dis       Date:  1978-08

9.  Bronchial hyperirritability in healthy subjects after exposure to ozone.

Authors:  J A Golden; J A Nadel; H A Boushey
Journal:  Am Rev Respir Dis       Date:  1978-08

10.  Evaluation of the severity of asthma: patients versus physicians.

Authors:  C S Shim; M H Williams
Journal:  Am J Med       Date:  1980-01       Impact factor: 4.965

View more
  63 in total

Review 1.  Childhood asthma--advances in pathogenesis.

Authors:  N Somu; N C Gowrishankar; L Subramaniam; D Vijayasekaran; B M Muhajir; A Balachandran
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

Review 2.  Discriminating measures of bronchodilator drug efficacy and potency.

Authors:  H Buck; M Parry-Billings
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

3.  Bronchial responsiveness and lung function in infants with lower respiratory tract illness over the first six months of life.

Authors:  J R Clarke; A Reese; M Silverman
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

4.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

Authors:  E F Juniper; G H Guyatt; R S Epstein; P J Ferrie; R Jaeschke; T K Hiller
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

5.  Factors relating to the development of respiratory symptoms in coffee process workers.

Authors:  K E Thomas; C J Trigg; P J Baxter; M Topping; J Lacey; B Crook; P Whitehead; J B Bennett; R J Davies
Journal:  Br J Ind Med       Date:  1991-05

6.  Atopy, bronchial responsiveness, and symptoms in wheezy 3 year olds.

Authors:  N M Wilson; S B Phagoo; M Silverman
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

7.  Diagnosis of asthma.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

8.  Protective effect by UCB JO28 against histamine and methacholine induced bronchial hyperreactivity.

Authors:  F P Maesen; J J Smeets; E Baltes; J P Rihoux
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Bronchial hyperresponsiveness following acute severe asthma.

Authors:  A Rabbat; J P Laaban; E Orvoën-Frija; M F Doré; A Achkar; J Rochemaure
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

10.  Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma.

Authors:  A Jatakanon; S Lim; S A Kharitonov; K F Chung; P J Barnes
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.